FAQ: How Does Obesity Affect PsA Outcomes?

In this FAQ, Libby Allen, a rheumatology nurse practitioner, explains how obesity impacts psoriatic arthritis outcomes and why it plays a critical role in disease severity and treatment response. Obesity is known to increase pro-inflammatory cytokines such as TNF-alpha (TNFA), IL-6, and IL-1B, creating a chronic low-grade inflammatory state that directly worsens psoriatic arthritis. This inflammation activates key immune pathways, including the IL-23 and IL-17 axis, which are central to psoriatic arthritis pathogenesis and progression. Patients with both obesity and psoriatic arthritis often experience poorer outcomes, including higher disease activity scores (DAPSA), increased joint pain, and reduced likelihood of achieving low disease activity or remission. Obesity also contributes to reduced effectiveness of conventional DMARDs and biologic therapies, making disease management more challenging. In addition to systemic inflammation, increased adiposity places mechanical stress on joints, further worsening pain and functional limitations. This video highlights the complex relationship between metabolic dysfunction and immune response, emphasizing that obesity is not just a comorbidity but a key driver of more severe psoriatic arthritis and diminished therapeutic response. Understanding this connection is essential for improving patient outcomes and optimizing treatment strategies in rheumatology. For more educational content, visit the RhAPP content rheum or explore the RhAPP ACE app.